The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
E7080 (lenvatinib) in addition to best supportive care (BSC) versus BSC alone in third-line or greater nonsquamous, non-small cell lung cancer (NSCLC).
Libor Havel
No relevant relationships to disclose
Jong-Seok Lee
No relevant relationships to disclose
Ki Hyeong Lee
No relevant relationships to disclose
Paolo Bidoli
Research Funding - Eisai
Joo-Hang Kim
Research Funding - Boehringer Ingelheim; Lilly; Pfizer; Roche; Sanofi
David Ferry
Research Funding - Eisai
Young-Chul Kim
No relevant relationships to disclose
Gyorgy Losonczy
No relevant relationships to disclose
Nicola Steele
No relevant relationships to disclose
In Sook Woo
No relevant relationships to disclose
Lea Forst
No relevant relationships to disclose
Yi Ma
No relevant relationships to disclose
Mark Joel Shelton
Employment or Leadership Position - Quintiles Transnational
Fabrina Bologna
No relevant relationships to disclose
Brian Huber
No relevant relationships to disclose
Harish P. Dave
No relevant relationships to disclose